Reprint

Anticancer Inhibitors

Edited by
August 2022
216 pages
  • ISBN978-3-0365-4920-0 (Hardback)
  • ISBN978-3-0365-4919-4 (PDF)

This book is a reprint of the Special Issue Anticancer Inhibitors that was published in

Chemistry & Materials Science
Medicine & Pharmacology
Summary

The word "cancer" is associated with at least 100 different pathologies, depending on the organ involved and the type of tumor developed. Cancer is a complex disease involving multiple pathogenetic mechanisms. Characterization of different types of cancers, which distinguishes them from healthy cells and other cancers, allows for the identification of specific targets for each individual tumor. The principle of chemotherapy is based on interference with the mechanisms that regulate the life and proliferation of cancer cells, causing their death. In recent years, there has been continuous progress in the development of therapeutic agents against cancer, which is ongoing.The Anticancer Inhibitors Special Issue focuses on new target-based anticancer agents that inhibit a specific target involved in the suppression of various types of cancer and the control of their chemoresistance.There is a collection of research and review articles on advances in drug discovery, design, and development of new inhibitor compounds with potency against various cancer types.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
breast cancer; tamoxifen; LY294002; synergism; apoptosis; cell cycle; tea (Camellia sinensis) flowers; BTFS; A2780/CP70 ovarian cancer cells; apoptosis; S phase cell cycle arrest; nicotinamide phosphoribosyltransferase; NAD+ biosynthesis; inhibitor; azacyclohexane; anticancer drug; drug design; enthalpy effect; NSCLC; Cathepsin K; cell proliferation; cell migration; cell invasion; mTOR; isatin-hydrazones; cytotoxicity; CDK2 inhibitor; ATP competitive inhibitor; ADME analysis; receptor tyrosine kinases; protein-protein interactions; protein engineering; directed evolution; angiogenesis; binding affinity; agonistic activity; saponins; phytochemicals; tea (Camellia sinensis) flower; ovarian cancer; autophagy; ZMYND8; tumorigenesis; epigenetic regulation; pro-oncogenic effects; tumor suppression; tacrine-coumarin derivatives; DNA; topoisomerases I, II; cytotoxicity; lung carcinoma cells; A549; chemotherapy; prodrug; drug targeting; overexpressed enzymes; ADC; ADEPT; GDEPT; LEAPT; PROTAC; cyclin-dependent kinase; cancer; resistance; small molecule inhibitors; PROTACs; statins; pancreatic cancer; DNA microarray; pitavastatin; cerivastatin; simvastatin; fluvastatin; atorvastatin; pravastatin; HMG-CoA reductase inhibitors; n/a